Loss of blood flow can cause irreversible heart muscle damage, making early detection the most important key to successful heart attack treatment. Abbott’s ARCHITECT STAT High Sensitive Troponin-I (hsTnl) test can measure very low levels of the protein, which allows doctors to evaluate whether patients are having a heart attack within two to four hours. This faster evaluation could allow doctors to reduce the time to diagnosis and treatment by several hours when compared to standard troponin tests. HsTnl is especially valuable for women, because their symptoms usually differ from those of men – contributing to underdiagnosis and undertreatment. Abbott’s Ireland team played an integral role in developing the ARCHITECT STAT assay, which is manufactured for global use at our diagnostics plant in Longford.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.